UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Which New Health Technologies Do We Need to Achieve an End to HIV/AIDS?

PLoS biology, 2016-03, Vol.14 (3), p.e1002372-e1002372

2016

Volltextzugriff (PDF)

Optimizing PCR Positivity Criterion for Detection of Herpes Simplex Virus DNA on Skin and Mucosa

Journal of Clinical Microbiology, 2007-05, Vol.45 (5), p.1618-1620

2007

Volltextzugriff (PDF)

E-104 Can non neutralizing antibodies be the basis for an effective HIV vaccine? Can we determine if RV 144 is “real or Memorex”?

Journal of acquired immune deficiency syndromes (1999), 2016-01, Vol.71 (Supplement 1), p.58

Corey, Larry

2016

Volltextzugriff (PDF)

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

The New England journal of medicine, 2021-02, Vol.384 (5), p.403-416

2021

Volltextzugriff (PDF)

Whither COVID-19 vaccines?

Nature biotechnology, 2020-10, Vol.38 (10), p.1132-1145

DeFrancesco, Laura

2020

Volltextzugriff (PDF)

Herpes Simplex Virus Shedding Rate: Surrogate Outcome for Genital Herpes Recurrence Frequency and Lesion Rates, and Phase 2 Clinical Trials End Point for Evaluating Efficacy of Antivirals

The Journal of infectious diseases, 2018-10, Vol.218 (11), p.1691-1699

2018

Volltextzugriff (PDF)

QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immmunization in humans

Vaccine, 2001-02, Vol.19 (15), p.2080-2091

2001

Volltextzugriff (PDF)

Impact of Point-of-Care Testing on the Management of Sexually Transmitted Infections in South Africa: Evidence from the HVTN702 Human Immunodeficiency Virus Vaccine Trial

Clinical infectious diseases, 2023-03, Vol.76 (5), p.881-889

2023

Volltextzugriff (PDF)

Nonprimary Maternal Cytomegalovirus Infection After Viral Shedding in Infants

The Pediatric infectious disease journal, 2018-07, Vol.37 (7), p.627-631

2018

Volltextzugriff (PDF)

Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study

The Lancet infectious diseases, 2014-05, Vol.14 (5), p.388-396

2014

Volltextzugriff (PDF)

Identifying predictors of increased quantities of human Herpesvirus 8 DNA detection at oropharyngeal and plasma sites among Ugandan adults with and without HIV and Kaposi Sarcoma

Infectious agents and cancer, 2012-04, Vol.7 (S1), p.O23-O23, Article O23

2012

Volltextzugriff (PDF)

Population pharmacokinetics analysis of VRC01, an HIV-1 broadly neutralizing monoclonal antibody, in healthy adults

mAbs, 2017-07, Vol.9 (5), p.792-800

2017

Volltextzugriff (PDF)

Multiple factors affect immunogenicity of DNA plasmid HIV vaccines in human clinical trials

Vaccine, 2015-05, Vol.33 (20), p.2347-2353

2015

Volltextzugriff (PDF)

In Memoriam: Scott M. Hammer, MD

Journal of the International AIDS Society, 2021-12, Vol.24 (12), p.e25856-n/a

2021

Volltextzugriff (PDF)

IL-17c promotes peripheral nerve growth during human herpes simplex virus type 2 (HSV-2) infection

The Journal of immunology (1950), 2017-05, Vol.198 (1_Supplement), p.61-61.9

2017

Volltextzugriff (PDF)

To Use or Not to Use Clade Specific Vaccines: A Central Question

AIDS research and human retroviruses, 2014-10, Vol.30 (S1), p.A90-A90

2014

Volltextzugriff (PDF)

Immunization with cocktail of HIV-derived peptides in montanide ISA-51 is immunogenic, but causes sterile abscesses and unacceptable reactogenicity

PloS one, 2010-08, Vol.5 (8), p.e11995

2010

Volltextzugriff (PDF)

IL28B Genotype Effects During Early Treatment with Peginterferon and Ribavirin in Difficult-to-Treat Hepatitis C Virus Infection

The Journal of infectious diseases, 2011-08, Vol.204 (3), p.419-425

2011

Volltextzugriff (PDF)

HLA targeting efficiency correlates with human T cell response magnitude and with mortality from influenza A infection (P6082)

The Journal of immunology (1950), 2013-05, Vol.190 (1_Supplement), p.49-49.21

2013

Volltextzugriff (PDF)

Incident Herpes Simplex Virus Type 2 Associated with HIV Infection in Phambili

AIDS research and human retroviruses, 2014-10, Vol.30 (S1), p.A29-A30

2014

Volltextzugriff (PDF)

Intentions to use preexposure prophylaxis among current phase 2B preventive HIV-1 vaccine efficacy trial participants

Journal of acquired immune deficiency syndromes (1999), 2013-07, Vol.63 (3), p.259-262

2013

Volltextzugriff (PDF)

Does participation in an HIV vaccine efficacy trial affect risk behaviour in South Africa?

Vaccine, 2013-04, Vol.31 (16), p.2089-2096

2013

Volltextzugriff (PDF)

Herpes Simplex Virus Shedding: Biomarker for Disease Severity and Response to Antivirals

Open forum infectious diseases, 2015-12, Vol.2 (suppl_1)

2015

Volltextzugriff (PDF)

Patterns of human herpesvirus-8 oral shedding among diverse cohorts of human herpesvirus-8 seropositive persons

Infectious agents and cancer, 2016-02, Vol.11 (7), p.7-7, Article 7

2016

Volltextzugriff (PDF)

1 – 25 von 210

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(177)
Mit Volltextzugriff
(173)

Publikationsform

4 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(208)
Russisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Which New Health Technologies Do We Need to Achieve an End to HIV/AIDS?

Optimizing PCR Positivity Criterion for Detection of Herpes Simplex Virus DNA on Skin and Mucosa

E-104 Can non neutralizing antibodies be the basis for an effective HIV vaccine? Can we determine if RV 144 is “real or Memorex”?

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Whither COVID-19 vaccines?

Herpes Simplex Virus Shedding Rate: Surrogate Outcome for Genital Herpes Recurrence Frequency and Lesion Rates, and Phase 2 Clinical Trials End Point for Evaluating Efficacy of Antivirals

QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immmunization in humans

Impact of Point-of-Care Testing on the Management of Sexually Transmitted Infections in South Africa: Evidence from the HVTN702 Human Immunodeficiency Virus Vaccine Trial

Safety and efficacy of the HVTN 503/Phambili Study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study

Nonprimary Maternal Cytomegalovirus Infection After Viral Shedding in Infants

Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study

Identifying predictors of increased quantities of human Herpesvirus 8 DNA detection at oropharyngeal and plasma sites among Ugandan adults with and without HIV and Kaposi Sarcoma

Population pharmacokinetics analysis of VRC01, an HIV-1 broadly neutralizing monoclonal antibody, in healthy adults

Multiple factors affect immunogenicity of DNA plasmid HIV vaccines in human clinical trials

In Memoriam: Scott M. Hammer, MD

IL-17c promotes peripheral nerve growth during human herpes simplex virus type 2 (HSV-2) infection

To Use or Not to Use Clade Specific Vaccines: A Central Question

Immunization with cocktail of HIV-derived peptides in montanide ISA-51 is immunogenic, but causes sterile abscesses and unacceptable reactogenicity

IL28B Genotype Effects During Early Treatment with Peginterferon and Ribavirin in Difficult-to-Treat Hepatitis C Virus Infection

HLA targeting efficiency correlates with human T cell response magnitude and with mortality from influenza A infection (P6082)

Incident Herpes Simplex Virus Type 2 Associated with HIV Infection in Phambili

Intentions to use preexposure prophylaxis among current phase 2B preventive HIV-1 vaccine efficacy trial participants

Does participation in an HIV vaccine efficacy trial affect risk behaviour in South Africa?

Herpes Simplex Virus Shedding: Biomarker for Disease Severity and Response to Antivirals

Patterns of human herpesvirus-8 oral shedding among diverse cohorts of human herpesvirus-8 seropositive persons

Suchergebnisse filtern